Neoadjuvant chemotherapy with gemcitabine for pancreatic cancer increases in situ expression of the apoptosis marker M30 and stem cell marker CD44

Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 94:153–156. 2001. View Article : Google Scholar : PubMed/NCBI

Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin. 58:71–96. 2008.

Conlon KC, Klimstra DS and Brennan MF: Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinico-pathologic analysis of 5-year survivors. Ann Surg. 223:273–279. 1996.PubMed/NCBI

Matsuno S, Egawa S, Fukuyama S, et al: Pancreatic cancer registry in Japan: 20 years of experience. Pancreas. 28:219–230. 2004.PubMed/NCBI

Kayahara M, Nagakawa T, Ueno K, et al: An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer. 72:2118–2123. 1993. View Article : Google Scholar : PubMed/NCBI

Burris HA, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI

Ottle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar

Golcher H, Brunner T, Grabenbauer G, et al: Preoperative chemo-radiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy. EJSO. 34:756–764. 2008. View Article : Google Scholar : PubMed/NCBI

Goses MJ, Dressen RC, Rutten HJ, et al: Prepoerative radio-chemotherapy is successful also in patients with locally advanced rectal cancer who have intrinsically high apoptotic tumors. Ann Oncol. 19:2026–2032. 2008. View Article : Google Scholar : PubMed/NCBI

Yang AD, Fan F, Camp ER, et al: Chronic oxaliplatin resistance induces epithelial-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153. 2006. View Article : Google Scholar : PubMed/NCBI

Tsukamoto H, Shibata K, Kajiyama H, et al: Irradiation-induced epithelial-mesencymal transition (EMT) related to invasive potential in endometrial carcinoma cells. Gynecol Oncol. 107:500–504. 2007. View Article : Google Scholar : PubMed/NCBI

Tajima H, Ohta T, Shoji Y, et al: Expression of epithelial-mesenchymal transition markers in locally recurrent hepatocellular carcinoma after radiofrequency ablation. Exp Therap Med. 1:347–350. 2010. View Article : Google Scholar

Shah AN, Summy JM, Zhang J, Park SI, Darikh NU and Gallick GE: Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol. 14:3629–3637. 2007. View Article : Google Scholar : PubMed/NCBI

Yang J, Mani SA, Donaher JL, et al: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 117:927–939. 2004. View Article : Google Scholar : PubMed/NCBI

Hay ED and Zuk A: Transformations between epithelium and mesenchyme: normal, pathological and experimentally induced. Am J Kidney Dis. 26:678–690. 1995. View Article : Google Scholar : PubMed/NCBI

Thiery JP: Epithelial-mesenchymal transitions in tumor progression. Nat Rev Cancer. 2:442–454. 2002. View Article : Google Scholar : PubMed/NCBI

Thiery JP and Sleeman JP: Complex networks orchestrate epithelial mesenchymal transitions. Nat Rev Mol Cell Biol. 7:131–142. 2006. View Article : Google Scholar : PubMed/NCBI

Kikuta K, Masamune A, Watanabe T, et al: Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells. Biochem Biophys Res Commun. 403:380–384. 2010. View Article : Google Scholar : PubMed/NCBI

Evans DB, Rich TA, Byrd DR, et al: Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 127:1335–1339. 1992. View Article : Google Scholar : PubMed/NCBI

Dive C, Smith RA, Garner E, et al: Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer. Br J Cancer. 102:577–582. 2010. View Article : Google Scholar : PubMed/NCBI

Du Z, Qin R, Wei C, et al: Pancreatic cancer cells resistant to chemoradiotherapy rich in ‘stem-cell-like’ tumor cells. Dig Dis Sci. 10:741–750. 2010.PubMed/NCBI

Hong SP, Wen J, Bang S, Park S and Song SY: CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer. 125:2323–2331. 2009. View Article : Google Scholar : PubMed/NCBI

Müerköster SS, Werbing V, Koch D, et al: Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma – epigenetic downregulation of caspase. Int J Cancer. 123:1751–1760. 2008.PubMed/NCBI

Yin T, Wang C, Liu T, Zhao G, Zha Y and Yang M: Expression of Snail in pancreatic cancer promotes metastasis and chemoresistsance. J Surg Res. 141:196–203. 2007. View Article : Google Scholar : PubMed/NCBI

Cauffert B, Mornex F, Bonnetain F, et al: Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cicplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 19:1592–1599. 2008.

Van Laethem JL, Hammel P, Mornex F, et al: Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012 /FFCD-9203/GERCOR phase II study. J Clin Oncol. 28:4450–4456. 2010.